Who are 99m-TC-PSMA-I&S's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, PIFLUFOLASTAT, [Ga-68]PSMA, 18F-rhPSMA-7.3, piflufolastat (18F), 177Lu-PSMA-617.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/99m-tc-psma-i-s.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

99m-TC-PSMA-I&S — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

99m-TC-PSMA-I&S (99m-TC-PSMA-I&S) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical. Area: Oncology.

phase 2 Radiopharmaceutical PSMA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

99m-TC-PSMA-I&S (99m-TC-PSMA-I&S) — IRCCS San Raffaele. 99m-TC-PSMA-I&S is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging of prostate cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
99m-TC-PSMA-I&S TARGET	99m-TC-PSMA-I&S	IRCCS San Raffaele	phase 2	Radiopharmaceutical	PSMA
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN		marketed	Radioligand Therapeutic Agent [EPC]	PSMA	2022-01-01
PIFLUFOLASTAT	PIFLUFOLASTAT		marketed	Radioactive Diagnostic Agent [EPC]	PSMA	2021-01-01
[Ga-68]PSMA	[Ga-68]PSMA	Norbert Avril, M.D.	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
18F-rhPSMA-7.3	18F-rhPSMA-7.3	Hackensack Meridian Health	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
piflufolastat (18F)	piflufolastat (18F)	Blue Earth Diagnostics	marketed	PSMA-targeting PET imaging agent	PSMA (prostate-specific membrane antigen)
177Lu-PSMA-617	177Lu-PSMA-617	European Organisation for Research and Treatment of Cancer - EORTC	phase 3	Radioligand therapy / Targeted radionuclide therapy	PSMA (Prostate-Specific Membrane Antigen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical class)

Amsterdam UMC, location VUmc · 1 drug in this class
Blue Earth Diagnostics · 1 drug in this class
Brigham and Women's Hospital · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
HTA Co., Ltd. · 1 drug in this class
IRCCS San Raffaele · 1 drug in this class
ITEL Telecomunicazioni Srl · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Michael C Roarke, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 99m-TC-PSMA-I&S — Competitive Intelligence Brief. https://druglandscape.com/ci/99m-tc-psma-i-s. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab